Title
The Arginine Methyltransferase PRMT6 Regulates DNA Methylation and Contributes to Global DNA Hypomethylation in Cancer
Date Issued
19 December 2017
Access level
open access
Resource Type
journal article
Author(s)
Hardikar S.
Zhong Y.
Gayatri S.
Dan J.
Strahl B.D.
Rothbart S.B.
Bedford M.T.
Chen T.
The University of Texas MD Anderson Cancer Center
Publisher(s)
Elsevier B.V.
Abstract
DNA methylation plays crucial roles in chromatin structure and gene expression. Aberrant DNA methylation patterns, including global hypomethylation and regional hypermethylation, are associated with cancer and implicated in oncogenic events. How DNA methylation is regulated in developmental and cellular processes and dysregulated in cancer is poorly understood. Here, we show that PRMT6, a protein arginine methyltransferase responsible for asymmetric dimethylation of histone H3 arginine 2 (H3R2me2a), negatively regulates DNA methylation and that PRMT6 upregulation contributes to global DNA hypomethylation in cancer. Mechanistically, PRMT6 overexpression impairs chromatin association of UHRF1, an accessory factor of DNMT1, resulting in passive DNA demethylation. The effect is likely due to elevated H3R2me2a, which inhibits the interaction between UHRF1 and histone H3. Our work identifies a mechanistic link between protein arginine methylation and DNA methylation, which is disrupted in cancer. Veland et al. find that PRMT6, an arginine methyltransferase responsible for histone H3 arginine 2 (H3R2) methylation, negatively regulates maintenance DNA methylation by impairing UHRF1 recruitment to chromatin. The authors also find that PRMT6 upregulation contributes to global DNA hypomethylation in cancer cells.
Start page
3390
End page
3397
Volume
21
Issue
12
Language
English
OCDE Knowledge area
Genética, Herencia
Oncología
Subjects
Scopus EID
2-s2.0-85039945293
PubMed ID
Source
Cell Reports
Sponsor(s)
We thank S. Richard for PRMT6 cDNA, K. Keyomarsi for the 76NF2V cell line, the shRNA and ORFeome Core at MD Anderson Cancer Center (MDACC) for the shRNA plasmids, and the Institute for Applied Cancer Science at MDACC for the PRMT inhibitor MS023. This work was supported by the Cancer Prevention and Research Institute of Texas ( CPRIT ; grants R1108 to T.C. and RP170002 to the NGS Core at MDACC) and the NIH (grants 1R01AI12140301A1 to T.C., R01GM110058 to B.D.S., R00CA181343 and R35GM124736 to S.B.R., DK062248 to M.T.B., and CA16672 to the CCSG Cores at MDACC). N.V., S.G., and J.D. were supported by scholarships from the Center for Cancer Epigenetics at MDACC. N.V. was also supported by a CPRIT Research Training Award ( RP140106 ) and was awarded the Andrew Sowell-Wade Huggins Scholarship Fund. T.C. is a CPRIT Scholar in Cancer Research.
Sources of information:
Directorio de Producción Científica
Scopus